Building blocks of tumor progression
This is the eighth article in a series written by each of the key members of the LRG Resistance Research Team. Several articles in the LRG newsletter from our GIST Resistance Research Team have been [...]
This is the eighth article in a series written by each of the key members of the LRG Resistance Research Team. Several articles in the LRG newsletter from our GIST Resistance Research Team have been [...]
GIST patients with a particular genetic mutation are more likely to respond to Gleevec than those without the mutation, reported Dr. Michael C. Heinrich at one of the plenary sessions of the annual conference of the American Society of Clinical Oncology, held May 14-17 in Orlando, Florida.
This is the second of a two-part series on KIT and PDGFRA mutations in GISTs, written collaboratively by Drs. Michael Heinrich and Christopher Corless, LRG research team members. Please refer to the May issue of our newsletter for the first part titled, “KIT & PDGFRA mutations in GIST: A to Z” by Dr. Heinrich.